Edition:
United States

CVS Health Corp (CVS.N)

CVS.N on New York Stock Exchange

81.78USD
24 Jan 2017
Change (% chg)

$0.53 (+0.65%)
Prev Close
$81.25
Open
$81.35
Day's High
$82.15
Day's Low
$81.12
Volume
1,285,149
Avg. Vol
1,920,241
52-wk High
$106.67
52-wk Low
$69.30

CVS.N

Chart for CVS.N

About

CVS Health Corporation, together with its subsidiaries (CVS Health), is a pharmacy company. The Company operates through three business segments: Pharmacy Services, Retail/LTC and Corporate. The Company offers a range of products and services, such as advising patients on their medications at its CVS Pharmacy locations,... (more)

Overall

Beta: 0.85
Market Cap(Mil.): $86,648.18
Shares Outstanding(Mil.): 1,066.44
Dividend: 0.50
Yield (%): 2.46

Financials

  CVS.N Industry Sector
P/E (TTM): 17.33 19.44 39.75
EPS (TTM): 4.69 -- --
ROI: 7.39 12.08 59.46
ROE: 13.93 13.71 67.21

Pharmacies lose class status bid in antitrust lawsuits against Caremark, Express Scripts

Independent pharmacies that have brought lawsuits accusing pharmacy benefit managers CVS Caremark and Express Scripts of conspiring to pay them less than chain pharmacies cannot bring their claims as class actions, a federal judge has ruled.

Jan 19 2017

CVS slashes price of Impax's EpiPen rival

Drugstore chain CVS Health Corp has cut the price of a generic version of Impax Laboratories Inc's emergency allergy injection, a device similar to Mylan NV's controversial EpiPen.

Jan 12 2017

CVS slashes price of Impax's EpiPen rival

Drugstore chain CVS Health Corp has cut the price of a generic version of Impax Laboratories Inc's emergency allergy injection, a device similar to Mylan NV's controversial EpiPen.

Jan 12 2017

CORRECTED-UPDATE 1-CVS slashes price of Impax's EpiPen rival

Jan 12 Drugstore chain CVS Health Corp has cut the price of a generic version of Impax Laboratories Inc's emergency allergy injection, a device similar to Mylan NV's controversial EpiPen.

Jan 12 2017

CORRECTED-CVS slashes price of Impax's emergency allergy shot

Jan 12 Drugstore chain CVS Health Corp has cut the price of a generic version of Impax Laboratories Inc's emergency allergy injection, a device similar to Mylan NV's controversial Epipen.

Jan 12 2017

Sanofi sues Novo Nordisk over diabetes drugs in the U.S.

France's Sanofi has filed a lawsuit in the United States accusing Novo Nordisk of falsely claiming that Sanofi insulin drugs would no longer be available for many U.S. patients so it could promote its competing drug.

Dec 27 2016

CVS cuts forecast after contract losses to Walgreens, shares dive

Drugstore chain and pharmacy benefits manager CVS Health Corp cut its profit forecast for this year and projected weak growth for 2017, saying it expected to lose more than 40 million retail prescriptions to other pharmacy chains, sending its shares down as much as 17 percent to a more than two-year low. | Video

Nov 08 2016

UPDATE 4-CVS cuts forecast after contract losses to Walgreens, shares dive

* Shares fall to a more than 2-year low (Adds Breakingviews link; updates shares)

Nov 08 2016

BRIEF-CVS reports Q3 adjusted EPS of $1.64

* Q3 GAAP earnings per share $1.43 from continuing operations

Nov 08 2016

BRIEF-CVS says "Caught a little bit off guard" in bid process for Prime, TRICARE network

* CVS Health executive says for Q4 2016 total same-store sales at retail are expected to be flat to down 1.75 percent -conf call

Nov 08 2016

Earnings vs. Estimates